1 The retractions came only weeks after BioMed Central.

During the past, the editor and editorial panel of a journal understood both scientific field it covered and the people employed in it, but it’s almost impossible to end up being sufficiently well linked when both editors and submissions come from worldwide. Having authors suggest the best reviewers may therefore seem like a good idea. In the aftermath of the recent scandals involving fake peer reviewers, many journals are determined to carefully turn off the reviewer-suggestion option on the manuscript-submission systems.But we’ve established a obvious treatment and monitoring plan in this study that’s secure and can be used in people.’ Gerdes carried out the extensive analysis over 3 years at NYIT. His colleagues include experts from the University of South Dakota, the guts for Center and Lung Study at The Feinstein Institute for Medical Research, and the University of Pisa, Italy.. ACT receives UK MHRA clearance for hESC-derived RPE cell trial for Stargardt’s Macular Dystrophy Advanced Cellular Technology, Inc. ;, a head in neuro-scientific regenerative medicine, announced today that it has received clearance from the U.K. Medicines and Healthcare items Regulatory Company to begin with treating patients as part of a Phase 1/2 medical trial for Stargardt’s Macular Dystrophy using retinal pigment epithelium produced from human embryonic stem cells .